ANAB:NASDAQ, AnaptysBio, Inc.

ANAB stock overview

AnaptysBio, Inc. (ANAB:NASDAQ) closed at $48.73 on October 23, 2026, up 1.31% on the day. The stock trades 32.7% below its 52-week high of $72.36 and 141.5% above its 52-week low of $20.18. Over the past year, it gained 39.0%. AnaptysBio, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $48.73
Day change: +1.31%
Volume: 468,090
Average volume: 503,465
Market cap: 1B+
52-week range: $20.18 – $72.36
50-day average: $52.85
200-day average: $49.87

Price action over the past year

In 252 trading sessions since October 23, 2025, ANAB closed higher on 129 days (51%). Its best day was April 24, 2026 (+14.84%) and its worst was October 27, 2025 (-31.22%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

Oct 23, 2026: Down 26.8% over 180 days, from $66.59 (Dips & Crashes scanner)
Oct 23, 2026: Trading sideways between $45.43 and $51.70 over 30 days (Sideways scanner)
Oct 19, 2026: News catalyst: Biotech (News Catalysts scanner)

ANAB news

Oct 19, 2026: Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
Oct 12, 2026: Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
Oct 9, 2026: AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
Oct 8, 2026: AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
Sep 26, 2026: AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance
Sep 26, 2026: AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
Sep 21, 2026: AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Sep 21, 2026: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

About AnaptysBio, Inc.

AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Similar stocks

Find more stocks like ANAB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.